Oculis Holding AG – NASDAQ:OCS
Oculis Holding AG stock price today
$17.95
+0.98
+5.84%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 2 days
Oculis Holding AG stock price monthly change
+49.03%
month
Oculis Holding AG stock price quarterly change
+49.03%
quarter
Oculis Holding AG stock price yearly change
+50.09%
year
Oculis Holding AG key metrics
Market Cap | 688.59M |
Enterprise value | N/A |
P/E | N/A |
EV/Sales | N/A |
EV/EBITDA | N/A |
Price/Sales | N/A |
Price/Book | N/A |
PEG ratio | N/A |
EPS | -1.64 |
Revenue | 876K |
EBITDA | -49.00M |
Income | -58.88M |
Revenue Q/Q | -7.30% |
Revenue Y/Y | -2.17% |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | -5594.06% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeOculis Holding AG stock price history
Oculis Holding AG stock forecast
Oculis Holding AG financial statements
| Jun 2023 | 250K | -12.87M | -5150.8% |
|---|---|---|---|
| Sep 2023 | 219K | -17.41M | -7951.14% |
| Dec 2023 | 185K | -12.49M | -6756.22% |
| Mar 2024 | 222K | -16.09M | -7249.1% |
| Dec 2023 | 185K | -12.49M | -6756.22% |
|---|---|---|---|
| Mar 2024 | 222K | -16.09M | -7249.1% |
| Sep 2025 | 188.94K | -12.80M | -6774.91% |
| Dec 2025 | 188.94K | -12.80M | -6774.91% |
Analysts Price target
Financials & Ratios estimates
| 2023-11-15 | -0.36 | -0.38 |
|---|---|---|
| 2024-03-18 | -0.42 | -0.38 |
| 2024-05-08 | -0.41 | -0.44 |
| Jun 2023 | 134844000 | 17.64M | 13.09% |
|---|---|---|---|
| Sep 2023 | 128941000 | 23.33M | 18.1% |
| Dec 2023 | 114353000 | 20.62M | 18.04% |
| Mar 2024 | 98713000 | 19.68M | 19.94% |
| Jun 2023 | -13.23M | -72.10M | 33.47M |
|---|---|---|---|
| Sep 2023 | -11.97M | -3.81M | 458K |
| Dec 2023 | -13.01M | 21.70M | 466K |
| Mar 2024 | -13.19M | -2.04M | 181K |
Oculis Holding AG alternative data
| Sep 2023 | 28 |
|---|---|
| Oct 2023 | 28 |
| Nov 2023 | 28 |
| Dec 2023 | 28 |
| Jan 2024 | 28 |
| Feb 2024 | 28 |
| Mar 2024 | 36 |
| Apr 2024 | 36 |
| May 2024 | 36 |
| Jun 2024 | 36 |
| Jul 2024 | 36 |
Oculis Holding AG other data
-
What's the price of Oculis Holding AG stock today?
One share of Oculis Holding AG stock can currently be purchased for approximately $17.95.
-
When is Oculis Holding AG's next earnings date?
Unfortunately, Oculis Holding AG's (OCS) next earnings date is currently unknown.
-
Does Oculis Holding AG pay dividends?
No, Oculis Holding AG does not pay dividends.
-
How much money does Oculis Holding AG make?
Oculis Holding AG has a market capitalization of 688.59M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 3.18% to 883K US dollars. Oculis Holding AG made a loss 88.8M US dollars in net income (profit) last year or -$0.44 on an earnings per share basis.
-
What is Oculis Holding AG's stock symbol?
Oculis Holding AG is traded on the NASDAQ under the ticker symbol "OCS".
-
What is Oculis Holding AG's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Oculis Holding AG?
Shares of Oculis Holding AG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
How many employees does Oculis Holding AG have?
As Jul 2024, Oculis Holding AG employs 36 workers.
-
When Oculis Holding AG went public?
Oculis Holding AG is publicly traded company for more then 4 years since IPO on 18 May 2021.
-
What is Oculis Holding AG's official website?
The official website for Oculis Holding AG is oculis.com.
-
How can i contact Oculis Holding AG?
Oculis Holding AG can be reached via phone at +41 58 810 01 82.
Oculis Holding AG company profile:
Oculis Holding AG
oculis.comExchange:
NASDAQ
Full time employees:
36
Industry:
Biotechnology
Sector:
Healthcare
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.
Bahnhofstrasse 7
Zug, 6300
Zug, 6300
CIK: 0001953530
ISIN: CH1242303498
:
